Buparvaquone loaded solid lipid nanoparticles for targeted delivery in theleriosis

被引:23
作者
Soni, Maheshkumar P. [1 ,3 ]
Shelkar, Nilakash [2 ]
Gaikwad, Rajiv V. [3 ]
Vanage, Geeta R. [2 ]
Samad, Abdul [3 ]
Devarajan, Padma V. [1 ]
机构
[1] Univ Bombay Vet Coll, Inst Chem Technol, Dept Pharmaceut Sci & Technol, Bombay, Maharashtra, India
[2] Univ Bombay Vet Coll, Natl Ctr Preclin Reproduct & Genet Toxicol, Natl Inst Res Reprod Hlth, Bombay, Maharashtra, India
[3] Univ Bombay Vet Coll, Maharashtra Anim & Fish Sci, Dept Vet Nucl Med, Bombay, Maharashtra, India
关键词
Buparavaquone; solid lipid nanoparticles; targeting efficiency; theileriosis;
D O I
10.4103/0975-7406.124309
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Buparvaquone (BPQ), a hydroxynaphthoquinone derivative, has been investigated for the treatment of many infections and is recommended as the gold standard for the treatment of theileriosis. Theileriosis, an intramacrophage infection is localized mainly in reticuloendotheileial system (RES) organs. The present study investigates development of solid lipid nanoparticles (SLN) of BPQ for targeted delivery to the RES. Materials and Methods: BPQ SLN was prepared using melt method by adding a molten mixture into aqueous Lutrol F68 solution (80 degrees C). Larger batches were prepared up to 6 g of BPQ with GMS: BPQ, 2:1. SLN of designed size were obtained using ultraturrax and high pressure homogenizer. A freeze and thaw study was used to optimize type and concentration of cryoprotectant with Sf: Mean particle size, Si: Initial particle size <1.3. Differential scanning calorimetry (DSC), powder X-ray diffraction (XRD) and scanning electron microscope (SEM) study was performed on optimized formulation. Formulation was investigated for in vitro serum stability, hemolysis and cell uptake study. Pharmacokinetic and biodistribution study was performed in Holtzman rat. Results: Based on solubility in lipid; glyceryl monostearate (GMS) was selected for preparation of BPQ SLN. Batches of BPQ SLN were optimized for average particle size and entrapment efficiency at <100 mg solid content. A combination of Solutol HS-15 and Lutrol F68 at 2% w/v and greater enabled the desired Sf/Si < 1.3. Differential scanning calorimetry and powder X-ray diffraction revealed decrease in crystallinity of BPQ in BPQ SLN while, scanning electron microscope revealed spherical morphology. BPQ SLN revealed good stability at 4 degrees C and 25 degrees C. Low hemolytic potential (<8%) and in vitro serum stability up to 5 h was observed. Cytotoxicity of SLN to the U937 cell was low. The macrophage cell line revealed high (52%) uptake of BPQ SLN in 1 h suggesting the potential to RES uptake. SLN revealed longer circulation and biodistrbution study confirmed high RES uptake (75%) in RES organs like liver lung spleen etc. Conclusion: The high RES uptake suggests BPQ SLN as a promising approach for targeted and improved delivery in theileriosis.
引用
收藏
页码:22 / 30
页数:9
相关论文
共 41 条
[1]   Factors affecting the clearance and biodistribution of polymeric nanoparticles [J].
Alexis, Frank ;
Pridgen, Eric ;
Molnar, Linda K. ;
Farokhzad, Omid C. .
MOLECULAR PHARMACEUTICS, 2008, 5 (04) :505-515
[2]  
Alidadi N, 2008, ASIAN J ANIM VET ADV, V3, P275
[3]   Solid lipid nanoparticles as a drug delivery system for peptides and proteins [J].
Almeida, Antonio J. ;
Souto, Eliana .
ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (06) :478-490
[4]   In vitro hemolysis:: Guidance for the pharmaceutical scientist [J].
Amin, Ketan ;
Dannenfelser, Rose-Marie .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (06) :1173-1176
[5]  
Anandaraja R, 2001, 12 NAT C VET PAR, VS-2: 01, P45
[6]  
Bansal GC, 2005, P NAT ACAD SCI INDIA, V75, P134
[7]   A NOVEL ASSAY TO DETERMINE THE HEMOLYTIC-ACTIVITY OF DRUGS INCORPORATED IN COLLOIDAL CARRIER SYSTEMS [J].
BOCK, TK ;
MULLER, BW .
PHARMACEUTICAL RESEARCH, 1994, 11 (04) :589-591
[8]   Solid lipid nanoparticles for applications in gene therapy: a review of the state of the art [J].
Bondi, Maria Luisa ;
Craparo, Emanuela Fabiola .
EXPERT OPINION ON DRUG DELIVERY, 2010, 7 (01) :7-18
[9]   Nanoparticles in cancer therapy and diagnosis [J].
Brigger, I ;
Dubernet, C ;
Couvreur, P .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (05) :631-651
[10]   PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery [J].
Chan, Juliana M. ;
Zhang, Liangfang ;
Yuet, Kai P. ;
Liao, Grace ;
Rhee, June-Wha ;
Langer, Robert ;
Farokhzad, Omid C. .
BIOMATERIALS, 2009, 30 (08) :1627-1634